IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Stamm et al

Application No. 09/899,026

Filed: July 6, 2001

Group Art Unit: 1615

Examiner: Sheikh

For: Fenofibrate Composition Having High Bioavailability and Method for Preparing It

Docket No: 107664.115US3

Commissioner of Patents PO Box 1450 Alexandria, VA 22303-1450

Information Disclosure Statement

This Information Disclosure Statement (IDS) is being filed concurrently with an RCE.

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form. A copy of each of the cited documents is submitted herewith.

The submission of this IDS does not represent that a search has been made and does not constitute an admission that the listed documents and/or European Oppositions are material to patentability or that the listed documents and/or European Oppositions are prior art.

Since this IDS is being filed with an RCE, no fee is due; however, the Commissioner is authorized to any necessary fees or credit any overpayments to Deposit Account No. 08-0219.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 Form with the next communication from the Patent Office.

Respectfully submitted,

Edward D. Grieff Registration No. 9

Date: July 21, 2005
WILMER CUTLER PICKERING HALE AND DORR LLP

1455 Pennsylvania Avenue, NW

Washington, DC 20004 Phone: (202) 942-8453

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Pap

Substitute for form

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUL 2 1 2005

(Use as many sheets as necessary)

of 4

Con	npiete it Kno	own			1
Application Number	09/899,026		- Far	111	-
Filing Date	July 6, 2001	gyri id		. ,	· i
First Named Inventor	Stamm		V.	-	
Art Unit	1615	Ø.	Visa politici	1.	1 1974
Examiner Name	Sheikh	As 3		(4)	
Attorney Docket Number	107664.115	US3			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>	US- 4,344,934	08-17-1982	Martin et al	
	<u> </u>				
		US- 2005/0032878 A1	02-10-2005	Deboeck et al	
		^{US-} 4,961,890	10-09-1990	Boyer	
		^{US-} 6,159,499	12-12-2000	Seth	
		^{US-} 6,207,198 B1	03-27-2001	Seth	
		^{US-} 6,248,355 B1	06-19-2001	Seth	
		^{US-} 4,795,643	01-03-1989	Seth	
		^{US-} 5,824,341	10-20-1998	Seth et al	
		^{US-} 6,096,341	08-01-2000	Seth	
		^{US-} 6,033,686	03-07-2000	Seth	
		^{US-} 6,048,547	04-11-2000	Seth et al	
		^{US-} 6,117,453	09-12-2000	Seth et al	
		^{US-} 6,348,469 B1	02-19-2002	Seth	
		^{US-} 4,436,743	03-13-1984	Schonafinger et al	
		US- 4,716,033	12-29-1987	Denick, Jr.	
		^{US-} 4,558,058	12-10-1985	Schonafinger et al	
		^{US-} 4,957,746	09-18-1990	Valducci	
		^{US-} 4,806,361	02-21-1989	Harrison et al	
		^{US-} 4,820,521	04-11-1989	Panoz et al	

	FORE	IGN PATENT DOCL	JMENTS TO THE TOTAL THE TOTAL TO THE TOTAL TOTAL TO THE T		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	۳°
	WO 96/21439	07-18-1996	Galephar P.R. Inc.		
	WO 03/013500	02-20-2003	Laboratoires SMB SA		
	EP 0 012 523	06-25-1980	American Home Products		
	WO 97/12580	04-10-1997	Pharma Pass		
	EP 0 179 583	04-30-1986	Merck & Co.		
	EP 0 193 958	09-10-1986	PPG Industries, Inc.		

Examiner	* ** (6.1	5 1 de de	134 my 1	the second second	 	Date	, .
Signature	-						Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE f 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14 PRADELLES	e required to respond to a concettor	Complete if Known
Substitute for form 1442 TRADE	Application Number	09/899,026
INFORMATION DISCLOSURE	Filing Date	July 6, 2001
STATEMENT BY APPLICANT	First Named Inventor	Stamm
	Art Unit	1615
(Use as many sheets as necessary)	Examiner Name	Sheikh
Sheet 2 of 4	Attorney Docket Number	107664.115 US3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
·		Opposition to EP 952 829 by Winthrop Arzneimittel GmbH filed March 31, 2005.	
		Opposition to EP 952 829 by Laboratoires SMB S.A. filed April 11, 2005.	
		Papers filed on April 15, 2005, by Ethypharm in Response to Patent Proprietor's Statement for Opposition to EP 952 829.	
		Guichard et al, "A New Formulation of Fenofibrate: Suprabioavailable Tablets," Current Medical Research and Opinion, 16(2):134-138 (2000).	
		Kuchiki et al, "Stable Solid Dispersion System Against Humidity," Yakuzaigaku, 44(1):31-37 (1984).	
		Pharmaceutical Pelletization Technology, Ghebre-Sallassie, Ed., Marcel Dekker, Inc., New York, Chapters 7 & 10 (1989).	
		Giunchedi et al, International Journal of Pharmaceutics, 130:41-47 (1996).	
		Shah et al, International Journal of Pharmaceutics, 125:99-106 (1995).	
		Suzuki et al, Chem. Pharm. Bull. 49(4):373-378 (2001).	
		Sangalli et al, Boll. Chim. Farmaceutico, 128(7-8):242-247 (1989).	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

09/899,026

no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for is

Sheet 3

INFORM STATEM

(Use a

ATION DISCLOSURE	Filing Date	July 6, 2001	i i	20074-00-	1.1-
the second of th	First Named Inventor	Stamm	T	- 10°	
ENT BY APPLICANT	Art Unit	1615		-(4):-	
is many sheets as necessary)	Examiner Name	Sheikh	90. 1 19b.	1	
of 4	Attorney Docket Number	107664.115	US3	I TITLE	12

Application Number

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (if known)}			Figures Appear	
		^{US-} 4,663,150	05-05-1987	Panoz et al		
		US-				
		US-				
		US-				
	<u> </u>	US-				
		US-				
-		US-				
	<u> </u>	US-				
		US-				
	-	US-				
		US-	-			
		US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
	<u> </u>	US-				

		FOREIGI	N PATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т ^б
		WO 96/04892	02-22-1996	Pharma Pass		
		EP 0 122 077	10-17-1984	Elan Corp.		
		EP 0 164 959	12-18-1985	Sterwin AG		
		EP 0 168 360	01-15-1986	Valducci		
		EP 0 239 541	09-30-1987	Warner-Lambert Co.		
		EP 0 256 933	02-24-1988	Ethypharm		

Examiner Signature	 3	- Transition of the second	14	Date Considered	**	. 3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

• (JUL 2 1 2005 %	PTO/SB/08B (07-05 Approved for use through 07/31/2006. OMB 0651-003	
Under the Paperwork Reduction Act of 1995, no persons Substitute for form 1449/PTO		nt and Trademark Office; U.S. DEPARTMENT OF COMMERCI on of information unless it contains a valid OMB control number Complete if Known	Ε
Substitute for form 1443/170	Application Number	09/899,026	-
INFORMATION DISCLOSURE	Filing Date	July 6, 2001	
STATEMENT BY APPLICANT	First Named Inventor	Stamm	

Art Unit

(Use as many sheets as necessary)

4

of

Sheet

4

Attorney Docket Number

Examiner Name

Stamm

Sheikh

107664.115 US3

1615

r 1997 11

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		European Pharmacopoeia, 3rd Edition, pages xiii-xvii and 127-131 (1996).	
		Remington's Pharmaceutical Sciences, 18th Edition, pages 1633-1665 (1985)	
 		Handbook of Pharmaceutical Excipients, 2nd Edition, pages 48-87, 141-144, 229-232, 252-261, 280-282, 392-401, 424-427, 448-450, 462-469, 491-493 (1994).	
		The United States Pharmacopoeia, Vol. 23, pages liv-lvi, 1791-1793, 1924-1938 (1994).	
		International Dictionary of Medicine and Biology, Volume 2, page 1774, John Wiley & Sons, Inc. (1986).	
		Boullay, "Microgrinding and Dissolution," S.T.P. Pharma, 1(4):296-299 (1985). (French-language document and English-language translation)	~
		CRC Handbook of Chemistry & Physics, 73rd Edition, Chapter 15, Page 32 (1992).	

Date Examiner Considered Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.